Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

BMJ Open
06 Jan 2022
https://pubmed.ncbi.nlm.nih.gov/34992118/

Saturday morning Q & A (2017 Conference) (LDN, low dose naltrexone)

Saturday afternoon Q & A (2017 Conference) (LDN, low dose naltrexone)

Can low-dose naltrexone relieve pain?

The Seattle times
12 Jan 2022
https://www.seattletimes.com/life/wellness/can-low-dose-naltrexone-relieve-pain/

At low doses (1 to 4.5 mg) it is prescribed to ease the pain and inflammation associated with conditions such as fibromyalgia, chronic pain syndrome, multiple sclerosis and Crohn’s disease

Low-dose Naltrexone for atopic dermatitis?

National Eczema Association
11 April 2019
https://nationaleczema.org/naltrexone/

Dr Phil Boyle - Low Dose Naltrexone for women's health (2019 Conference) (LDN, low dose naltrexone)

This Presentation was Recorded for The LDN Research Trust 2019 Conference

Drug relieves chronic pain without the addiction risk

Futurity
17 February 2021
https://www.futurity.org/naltrexone-chronic-pain-addiction-opioids-2519…

A low dose of a drug called naltrexone is a good option for patients with orofacial and chronic pain, without the risk of addiction, researchers report.

Comments on "Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review"

Pain Physician
December 2021
https://www.painphysicianjournal.com/current/pdf?article=NzM4NA%3D%3D

In Response Comments on "Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review"

Pain Physician
December 2021
https://www.painphysicianjournal.com/current/pdf?article=NzM4NQ%3D%3D